Evenamide
规格
| Cas Number | 1092977-61-1(DMSO) |
| 规格或纯度 | 10mM in DMSO |
| 包装 | 1ml |
产品信息
| 品牌 | 阿拉丁 |
| 浓度 | 10mM in DMSO |
| 过滤标签 | Sodium Channel,膜转运器/离子通道,Compound libraries |
| 储存温度 | -80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | 埃文酰胺（NW-3509）是一种口服电压门控钠通道（VGSC）阻断剂（K i = 0.4 µM），用于研究精神分裂症。埃文酰胺在精神错乱、躁狂症、抑郁症和攻击性等多种啮齿动物模型中均有疗效。 |
| 英文描述 |
Evenamide (NW-3509) is an orally available voltage-gated sodium channel (VGSC) blocker ( K i =0.4 µM) for the research of schizophrenia. Evenamide shows efficacy in a broad spectrum of rodent models of psychosis, mania, depression, and aggressiveness In Vitro Evenamide selectively blocks voltage-gated sodium channels (VGSCs) in a voltage-and use-dependent manner (K i =0.4 µM) and modulates sustained repetitive firing without inducing impairment of the normal neuronal excitability. Evenamide does not bind, inhibit or interact with over 130 receptors, enzymes, or transporters. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Evenamide is active in a wide range of psychiatric animal models in monotherapy and addon to antipsychotics. Evenamide is effective in attenuating the social interaction deficit in Cl 395 (PCP)-impaired rats (MED=1 mg/kg po). MCE has not independently confirmed the accuracy of these methods. They are for reference only. IC50& Target:Sodium channel |